SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

12 Months Ended

Mar. 29, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Selected information by reportable segment is presented below:

(In thousands)	2025		2024		2023
Net sales
Plasma	$	535,431	$	569,535	$	499,916
Blood Center	261,124		283,231		287,034
Hospital	564,269		456,289		381,710
Net sales by business unit	$	1,360,824	$	1,309,055	$	1,168,660

Significant segment expenses and operating performance
Plasma
Cost of goods sold	$	237,050	$	264,042	$	254,474
Selling, general and administrative	98,418		109,729		106,006
Research and development	15,453		13,797		14,690
Plasma operating income	$	184,510	$	181,967	$	124,746
Blood Center
Cost of goods sold	$	142,512	$	165,564	$	144,364
Selling, general and administrative	60,023		67,339		74,024
Research and development	5,770		7,956		4,374
Blood Center operating income	$	52,819	$	42,372	$	64,272
Hospital
Cost of goods sold	$	199,499	$	167,172	$	147,831
Selling, general and administrative	241,760		209,680		181,368
Research and development	34,035		27,239		23,096
Hospital operating income	$	88,975	$	52,198	$	29,415
Corporate and unallocated expenses
Amortization of acquired assets	$	(63,217)	$	(35,378)	$	(32,640)
Acquisition, integration and divestiture related costs	(22,904)		(11,249)		411
Restructuring and restructuring related costs	(21,158)		(23,588)		(11,549)
Digital transformation costs	(20,273)		(15,667)		(4,536)
Contingent Consideration	23,022		—		—
Other(1)	43		(25,772)		(14,086)
Operating income	221,817		164,883		156,033
Interest and other expense, net	(9,746)		(13,018)		(14,630)
Income before provision for income taxes	$	212,071	$	151,865	$	141,403
(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2® related charges and gain on divestiture.

Net revenues by business unit are as follows:

(In thousands)		2025		2024		2023
	Plasma	$	535,431	$	569,535	$	499,916
	Apheresis	213,134		211,173		207,618
	Whole Blood	47,990		72,058		79,416
	Blood Center	261,124		283,231		287,034
	Interventional Technologies	255,019		174,285		126,717
	Blood Management Technologies	309,250		282,004		254,993
	Hospital	$	564,269	$	456,289	$	381,710
Total net revenues		$	1,360,824	$	1,309,055	$	1,168,660

(In thousands)	2025		2024		2023
Depreciation and amortization
Plasma	$	48,264	$	45,712	$	41,612
Blood Center	10,077		13,391		13,927
Hospital	57,245		38,112		37,768
Total depreciation and amortization (excluding impairment charges)	$	115,586	$	97,215	$	93,307

(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
Plasma	$	189,833	$	211,121
Blood Center	40,337		54,262
Hospital	53,882		45,979
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.

Segment Information by Geographic Area

Selected information by operating regions is presented below:

(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
United States	$	217,212	$	246,473
Japan	1,250		1,597
Europe	20,024		15,310
Rest of Asia	28,705		26,728
Other	16,861		21,254
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.

(In thousands)	2025		2024		2023
Net revenues
United States	$	1,010,918	$	970,007	$	842,897
Japan	62,408		58,087		61,295
Europe	175,655		160,142		156,680
Rest of Asia	92,305		107,536		104,135
Other	19,538		13,283		3,653
Total net revenues	$	1,360,824	$	1,309,055	$	1,168,660